GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » EBITDA Margin %

China Resources Pharmaceutical Group (HKSE:03320) EBITDA Margin % : 4.96% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. China Resources Pharmaceutical Group's EBITDA for the six months ended in Dec. 2023 was HK$6,305 Mil. China Resources Pharmaceutical Group's Revenue for the six months ended in Dec. 2023 was HK$127,025 Mil. Therefore, China Resources Pharmaceutical Group's EBITDA margin for the quarter that ended in Dec. 2023 was 4.96%.


China Resources Pharmaceutical Group EBITDA Margin % Historical Data

The historical data trend for China Resources Pharmaceutical Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group EBITDA Margin % Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.22 6.32 5.90 6.13 6.31

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 7.59 4.71 7.52 4.96

Competitive Comparison of China Resources Pharmaceutical Group's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's EBITDA Margin % falls into.



China Resources Pharmaceutical Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

China Resources Pharmaceutical Group's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=16877.997/267651.942
=6.31 %

China Resources Pharmaceutical Group's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=6304.855/127025.342
=4.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Pharmaceutical Group  (HKSE:03320) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


China Resources Pharmaceutical Group EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines